SCHEMBL5541429

SCHEMBL5541429

[CH2]c1ccccc1NCc1cc(C)ccc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MAPT P10636 8/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4C Q9H3R0 1/20 0.46
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.40
RECQL P46063 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
MAPK1 P28482 3/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 2/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.38
CRHBP P24387 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545685 0.87 MAPT (0.51) GAANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL688010 0.83 MAPT (0.53) GAAMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL5542074 0.77 MAPT (0.40) GAANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL5542578 0.76 HTT (0.52) GAANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL5544368 0.75 MAPT (0.58) GAAMAPTSMN1; SMN2KDM4CALDH1A1
SCHEMBL5545641 0.75 BRD4 (0.46) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL15540361 0.75 MAPT (0.58) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL5544031 0.75 ADRA2C (0.41) GAAMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL5538928 0.73 CYP3A4 (0.48) GAAMAPTALDH1A1MEN1KMT2A
SCHEMBL6484133 0.72 GAA (0.44) GAANPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.